Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Executive Summary

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

You may also be interested in...



Boehringer Buys Antibody-Drug Conjugates Biotech NBE For €1.18bn

Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.

Why BI Bid Farewell To Biosimilars

The German group pharma's chief told Scrip "innovation drives the business" and confirmed that biosimilars have been abandoned apart from its Humira version Cyltezo in the US.

AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel